Huangqi Shengmai Yin Ameliorates Myocardial Fibrosis by Activating Sirtuin3 and Inhibiting TGF-β/Smad Pathway

Overview

Journal Front Pharmacol

Date 2021 Sep 6

PMID 34483934

Citations 3

Authors

Jianheng Pan

Zhanhong Cao

Chunqiu Fang

Yuting Lei

Jiaming Sun

Xiaowei Huang

Dong Han

Affiliations

Soon will be listed here.

Abstract

Myocardial fibrosis (MF) is an important pathological process in which a variety of cardiovascular diseases transform into heart failure. The main manifestation of MF is the excessive deposition of collagen in the myocardium. Here, we explored whether Huangqi Shengmai Yin (HSY) can inhibit isoprenaline (ISO)-induced myocardial collagen deposition in rats, thereby reducing the cardiac dysfunction caused by MF. The results of echocardiography showed that HSY upregulated fractional shortening and ejection fraction, and reduced the left ventricular systolic dysfunction in the rats with MF. Pathological results showed that HSY protected myocardium, inhibited apoptosis, and effectively reduced collagen deposition. HSY also inhibited the expression of collagen I and III and α-smooth muscle actin (α-SMA) in the heart tissue. HSY increased the expression of Sirtuin 3 (Sirt3) and inhibited the protein levels of the components in the transforming growth factor-β (TGF-β)/Smad pathway. At the same time, it also regulated the expression of related proteins in the matrix metalloproteinases family. In summary, HSY played a therapeutic role in rats with ISO-induced MF by protecting myocardium and inhibiting collagen deposition. Therefore, HSY is a potential therapeutic agent for ameliorating MF.

Citing Articles

Energy metabolism in health and diseases.

Liu H, Wang S, Wang J, Guo X, Song Y, Fu K Signal Transduct Target Ther. 2025; 10(1):69.

PMID: 39966374 PMC: 11836267. DOI: 10.1038/s41392-025-02141-x.

The beneficial health effects of puerarin in the treatment of cardiovascular diseases: from mechanisms to therapeutics.

Wan Q, Lu Q, Luo S, Guan C, Zhang H Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(10):7273-7296.

PMID: 38709267 DOI: 10.1007/s00210-024-03142-3.

Melatonin enhances captopril mediated cardioprotective effects and improves mitochondrial dynamics in male Wistar rats with chronic heart failure.

El-Sayed S, Abdelhamid A, ZeinElabdeen S, El-Wafaey D, Moursi S Sci Rep. 2024; 14(1):575.

PMID: 38182706 PMC: 10770053. DOI: 10.1038/s41598-023-50730-z.

Targeting Mitochondrial Sirtuins in Age-Related Neurodegenerative Diseases and Fibrosis.

Xiao H, Xie Y, Xi K, Xie J, Liu M, Zhang Y Aging Dis. 2023; 14(5):1583-1605.

PMID: 37196115 PMC: 10529758. DOI: 10.14336/AD.2023.0203.

References

Francis Stuart S, De Jesus N, Lindsey M, Ripplinger C . The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction. J Mol Cell Cardiol. 2016; 91:114-22. PMC: 4764395. DOI: 10.1016/j.yjmcc.2015.12.024. View

He X, Liu Q, Peng W, Huang Y, Wu C . Bioactivities and serum pharmacochemistry of Qi-Wei-Xiao-Yan-Tang. Pharm Biol. 2013; 51(5):629-34. DOI: 10.3109/13880209.2012.761243. View

Dixon J, Spinale F . Pathophysiology of myocardial injury and remodeling: implications for molecular imaging. J Nucl Med. 2010; 51 Suppl 1:102S-106S. PMC: 3045843. DOI: 10.2967/jnumed.109.068213. View

Krenek P, Kmecova J, Kucerova D, Bajuszova Z, Musil P, Gazova A . Isoproterenol-induced heart failure in the rat is associated with nitric oxide-dependent functional alterations of cardiac function. Eur J Heart Fail. 2009; 11(2):140-6. PMC: 2639419. DOI: 10.1093/eurjhf/hfn026. View

Chen T, Li J, Liu J, Li N, Wang S, Liu H . Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGF-β/Smad3 pathway. Am J Physiol Heart Circ Physiol. 2014; 308(5):H424-34. DOI: 10.1152/ajpheart.00454.2014. View

McDonald H, Peart J, Kurniawan N, Galloway G, Royce S, Samuel C . Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction. Physiol Rep. 2018; 6(9):e13699. PMC: 5949285. DOI: 10.14814/phy2.13699. View

Gourdie R, Dimmeler S, Kohl P . Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease. Nat Rev Drug Discov. 2016; 15(9):620-638. PMC: 5152911. DOI: 10.1038/nrd.2016.89. View

Li L, Zhao Q, Kong W . Extracellular matrix remodeling and cardiac fibrosis. Matrix Biol. 2018; 68-69:490-506. DOI: 10.1016/j.matbio.2018.01.013. View

Yu B, Wang W . Cardioprotective Effects of Morroniside in Rats Following Acute Myocardial Infarction. Inflammation. 2017; 41(2):432-436. DOI: 10.1007/s10753-017-0699-x. View

10.

Mohammed S, Hussain S, Mirzoyev S, Edwards W, Maleszewski J, Redfield M . Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015; 131(6):550-9. PMC: 4324362. DOI: 10.1161/CIRCULATIONAHA.114.009625. View

11.

Sun R, Wang J, Zheng Y, Li X, Xie T, Li R . Traditional Chinese medicine baoxin decoction improves cardiac fibrosis of rats with dilated cardiomyopathy. Exp Ther Med. 2017; 13(5):1900-1906. PMC: 5443197. DOI: 10.3892/etm.2017.4223. View

12.

Essick E, Sam F . Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor. Int J Hypertens. 2011; 2011:346985. PMC: 3124304. DOI: 10.4061/2011/346985. View

13.

Su H, Zeng H, Liu B, Chen J . Sirtuin 3 is essential for hypertension-induced cardiac fibrosis via mediating pericyte transition. J Cell Mol Med. 2020; 24(14):8057-8068. PMC: 7348169. DOI: 10.1111/jcmm.15437. View

14.

Mallick A, Januzzi Jr J . Biomarkers in acute heart failure. Rev Esp Cardiol (Engl Ed). 2015; 68(6):514-25. DOI: 10.1016/j.rec.2015.02.009. View

15.

Wei Y, Wu Y, Feng K, Zhao Y, Tao R, Xu H . Astragaloside IV inhibits cardiac fibrosis via miR-135a-TRPM7-TGF-β/Smads pathway. J Ethnopharmacol. 2019; 249:112404. DOI: 10.1016/j.jep.2019.112404. View

16.

Lv S, Yuan P, Dong J, Lu C, Li M, Qu F . QiShenYiQi pill improves the reparative myocardial fibrosis by regulating autophagy. J Cell Mol Med. 2020; 24(19):11283-11293. PMC: 7576289. DOI: 10.1111/jcmm.15695. View

17.

Masci P, Schuurman R, Andrea B, Ripoli A, Coceani M, Chiappino S . Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: a contrast-enhanced cardiovascular magnetic study. Circ Cardiovasc Imaging. 2013; 6(5):790-9. DOI: 10.1161/CIRCIMAGING.113.000438. View

18.

Zhang K, Qian X, Zheng W, Cai M, Ma Y, Zhang D . Synthesis and In Vitro anti-HCV and Antitumor Evaluation of Schisandronic Acid Derivatives. Med Chem. 2020; 17(9):974-982. DOI: 10.2174/1573406416999200818150053. View

19.

Wang Q, Yu X, Xu H, Zhao X, Sui D . Ginsenoside Re Improves Isoproterenol-Induced Myocardial Fibrosis and Heart Failure in Rats. Evid Based Complement Alternat Med. 2019; 2019:3714508. PMC: 6332977. DOI: 10.1155/2019/3714508. View

20.

Wang J, Shen W, Zhang J, Jia C, Xie M . Stevioside attenuates isoproterenol-induced mouse myocardial fibrosis through inhibition of the myocardial NF-κB/TGF-β1/Smad signaling pathway. Food Funct. 2019; 10(2):1179-1190. DOI: 10.1039/c8fo01663a. View